PHILADELPHIA — In this video exclusive, Pam R. Taub, MD, FACC, cardiologist and associate professor of medicine at University of California, San Diego, highlights the benefits of PCSK9 inhibitors in high-risk patients.
Taub discusses recent data that have demonstrated benefit of PCSK9 inhibitors for reducing major adverse CV events and in subgroups of high-risk patients such as those with multivessel disease, peripheral artery disease, type 2 diabetes and elevated lipoprotein A.
Watch the video for more.

Source link